Raise closed, search for fresh raises on Seedstage

San Jose, CA

Advancing the commercialization of a non-invasive device for rapid skin cancer detection.

• Breakthrough diagnostic device: AURA™ uses Raman spectroscopy to detect skin cancer in under two seconds.
• Non-invasive technology: Reduces the need for biopsies while increasing diagnostic speed and accuracy.
• Experienced leadership: CEO previously led a public tech company to a multi-billion dollar valuation.
• Extensive clinical development: Over $20 million invested and validated in major clinical studies.
• Strong market potential: Targets the $8.9 billion U.S. skin cancer market with potential to expand into other cancer types.

Vita Imaging is raising funds to support the commercialization and regulatory clearance of AURA™, a non-invasive device that detects skin cancer in less than two seconds using advanced Raman spectroscopy. After over two decades of research, clinical validation, and more than $20 million in development, the company is now entering the final stages of FDA review. Proceeds from this raise will help advance the path to market launch, scale manufacturing, and fund the initial commercial rollout targeting dermatology clinics. In addition to finalizing regulatory steps, Vita Imaging aims to expand its presence in the U.S. healthcare system and explore international opportunities following approval.

AURA™ represents a potential breakthrough in the early detection of skin cancer by offering a safer, faster, and more accurate alternative to biopsies. The device is designed to address a significant medical and financial burden, with over six million Americans treated annually for skin cancer. Backed by a robust patent portfolio, a seasoned executive team, and partnerships with leading research institutions, Vita Imaging is also laying the foundation for a broader diagnostic platform. Future applications may include detecting various other cancers using the same core technology. With a strong product roadmap and a clear market need, this raise provides investors the opportunity to support a healthcare innovation that could improve diagnostic precision and reduce overall system costs.

Company Info

Vita Imaging develops a rapid, non-invasive skin cancer detection device using Raman spectroscopy, with broader applications in cancer diagnostics.

Vita Imaging is a medical technology company based in San Jose, California, developing AURA™, a non-invasive diagnostic device designed to detect skin cancer in under two seconds. Using Raman spectroscopy, AURA™ identifies benign or malignant lesions by analyzing molecular fingerprints of skin cells, offering a safer, faster, and more accurate alternative to traditional biopsies. The technology was developed over two decades with more than $20 million invested in research and has undergone extensive clinical validation. It is now in the final stages of FDA premarket approval and is being prepared for commercial launch.

The device is aimed initially at dermatology clinics, with future plans to expand to primary care settings, medical spas, and other healthcare facilities. In addition to addressing the $8.9 billion U.S. skin cancer market, Vita Imaging plans to use collected diagnostic data to enhance AI accuracy and expand the platform to other cancers like stomach, lung, colon, and brain. The company is supported by a robust patent portfolio, strategic academic partnerships, and a seasoned leadership team. Vita Imaging’s roadmap includes international expansion, FDA approval by late 2025, and future development of diagnostic solutions for other cancer types.